Combination of weight loss drugs better for pre-BMS patients than GLP-1s or dieting alone
- owenhaskins
- 2 days ago
- 3 min read
A study by Pennington Biomedical Research Center's Metamor Institute researchers that evaluated the use of different types of pre-surgery treatments, including the use of strong weight-loss medications such as multi-modal anti-obesity medications (mmAOMs), GLP-1s, and traditional diet and exercise to determine which option was most effective, has found that patients who used multiple medications lost the most weight prior to surgery.
For patients with a body mass index (BMI) of 70 or higher, metabolic surgery is a highly effective treatment for this form of extreme obesity. In preparing for this minimally invasive surgery and to increase perioperative safety, it is important for patients to lose weight, especially those with a high BMI.
While traditional strategies for perioperative weight loss include dieting and exercise, GLP-1 receptor agonists (GLP-1s) have been increasingly used in recent years. Prior studies have shown that achieving 5% weight loss prior to metabolic surgery may be associated with reduced postoperative complications, but this is often difficult to achieve with diet alone.
On average, patients taking mmAOMs lost more than 13% of their total body weight, compared with 8.1% of body weight for those taking only GLP-1s and nearly 6% for those on the supervised weight-loss strategies of diet and exercise.
"We have demonstrated the long-term efficacy and health benefits of metabolic surgery for individuals with severe obesity. However, access to surgery is often delayed, sometimes indefinitely, due to the limited success of current preoperative weight-loss strategies," said Michael Kachmar, a surgeon at the Metamor Institute at Pennington Biomedical."Our study shows those patients who used multiple anti-obesity medication lost more weight faster, suggesting that preparation for metabolic surgery in very high BMI patients may be better served with mmAOMs."
The research showed that the greatest mmAOM weight loss occurred after approximately 51 weeks of application, though this weight loss slowed after approximately 88 weeks. This slowing in weight loss can result from physiological adaptation to the medication or difficulty remaining with the treatment due to side effects or costs. However, mmAOM provides a predictable window in which meaningful weight loss can occur to better prepare patients with a high BMI for metabolic surgery.
Researchers indicate that further studies are needed to enhance strategies to tailor treatments to patients based on their needs, but the measurable benefits of mmAOMs position them as a leading option for metabolic surgery preparation. Still, even a small weight loss can improve surgical outcomes and reduce liver size and abdominal fat. All study groups lost weight, which, regardless of the amounts lost, is crucial for improved safety.
"Metamor Institute has positioned itself as a leader in treating obesity in a comprehensive manner, from medical and therapeutic interventions to metabolic surgery," said Dr John Kirwan, Executive Director of Pennington Biomedical. "The Institute is in a class of its own, as recent research is shining a much-needed spotlight on the tailored, thoughtful approach needed for the management of extreme obesity, which is increasing at an alarming rate."
This latest study from Metamor and Pennington Biomedical gives new and much-needed research attention to patients with BMI greater than 60 kilograms per square metre.
The findings were featured in the paper, ‘Multi-modal neo-adjuvant anti-obesity medications may be more effective than medically supervised weight loss or GLP-1 therapy alone in preparing BMI≥70 patients for metabolic surgery’, published in the International Journal of Obesity
To access this paper, please click here